A randomized study of the effect of mifepristone alone or in conjunction with ethinyl estradiol on ovarian function in women using the etonogestrel-releasing subdermal implant, Implanon®

Edith Weisberg, Horatio B. Croxatto, John K. Findlay, Henry G. Burger, Ian S. Fraser

Resultado de la investigación: Article

8 Citas (Scopus)

Resumen

Background: Mifepristone alone or in combination with ethinyl estradiol (EE) can effectively stop an episode of uterine bleeding in women using the etonogestrel-releasing contraceptive implant, Implanon® but could impair contraceptive efficacy. Aim: To examine the effects of administration of mifepristone alone or with EE on ovarian function and cervical mucus consistency in women using Implanon. Study Design: Women using Implanon were randomized to mifepristone 25 mg twice daily on day 1 plus placebo 1 daily for 4 days or plus EE 20 mcg daily for days 2-5. Measurements of serum estradiol (E 2), progesterone (P 4), luteinizing hormone (LH), follicle-stimulating hormone (FSH), cervical mucus examination and maximal follicle size (by vaginal ultrasound) were carried out at various times. Results: Following mifepristone intake, there was a dramatic increase in E 2 levels ranging from 543 to 1183 pmol/L (p=.000), which was not correlated with maximal follicle size or preceded by LH or FSH increase. The increase in E 2 triggered an LH increase resulting in development of a luteinized follicle in four women with no evidence of ovulation. One of these women had estradiol and progesterone levels suggestive of ovulation, but no corpus luteum was seen. Almost all women had very low mucus scores, which did not correlate with E 2 levels. Discussion: Despite a transient increase in E 2 levels after mifepristone, there was no evidence of subsequent ovulation irrespective of whether they also received EE. The mechanism by which mifepristone in the presence of etonogestrel results in a rapid increase in E 2 levels remains unclear and could not be related to any significant changes in FSH, LH, ovarian follicle dynamics or subsequent possible ovulation. Conclusion: Pregnancy is very unlikely to occur if mifepristone and EE are given during use of Implanon to stop an episode of bleeding.

Idioma originalEnglish
Páginas (desde-hasta)600-608
Número de páginas9
PublicaciónContraception
Volumen84
N.º6
DOI
EstadoPublished - 1 dic 2011

Huella dactilar

Mifepristone
Ethinyl Estradiol
Luteinizing Hormone
Ovulation
Follicle Stimulating Hormone
Cervix Mucus
Contraceptive Agents
Progesterone
Estradiol
Ovarian Follicle
Uterine Hemorrhage
Corpus Luteum
Mucus
etonogestrel
Placebos
Hemorrhage
Pregnancy
Serum

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology

Citar esto

@article{62427fa1f45d44c794fea129a1e16818,
title = "A randomized study of the effect of mifepristone alone or in conjunction with ethinyl estradiol on ovarian function in women using the etonogestrel-releasing subdermal implant, Implanon{\circledR}",
abstract = "Background: Mifepristone alone or in combination with ethinyl estradiol (EE) can effectively stop an episode of uterine bleeding in women using the etonogestrel-releasing contraceptive implant, Implanon{\circledR} but could impair contraceptive efficacy. Aim: To examine the effects of administration of mifepristone alone or with EE on ovarian function and cervical mucus consistency in women using Implanon. Study Design: Women using Implanon were randomized to mifepristone 25 mg twice daily on day 1 plus placebo 1 daily for 4 days or plus EE 20 mcg daily for days 2-5. Measurements of serum estradiol (E 2), progesterone (P 4), luteinizing hormone (LH), follicle-stimulating hormone (FSH), cervical mucus examination and maximal follicle size (by vaginal ultrasound) were carried out at various times. Results: Following mifepristone intake, there was a dramatic increase in E 2 levels ranging from 543 to 1183 pmol/L (p=.000), which was not correlated with maximal follicle size or preceded by LH or FSH increase. The increase in E 2 triggered an LH increase resulting in development of a luteinized follicle in four women with no evidence of ovulation. One of these women had estradiol and progesterone levels suggestive of ovulation, but no corpus luteum was seen. Almost all women had very low mucus scores, which did not correlate with E 2 levels. Discussion: Despite a transient increase in E 2 levels after mifepristone, there was no evidence of subsequent ovulation irrespective of whether they also received EE. The mechanism by which mifepristone in the presence of etonogestrel results in a rapid increase in E 2 levels remains unclear and could not be related to any significant changes in FSH, LH, ovarian follicle dynamics or subsequent possible ovulation. Conclusion: Pregnancy is very unlikely to occur if mifepristone and EE are given during use of Implanon to stop an episode of bleeding.",
keywords = "Ethinyl estradiol, Etonogestrel, Implanon{\circledR}, Mifepristone, Subdermal implant",
author = "Edith Weisberg and Croxatto, {Horatio B.} and Findlay, {John K.} and Burger, {Henry G.} and Fraser, {Ian S.}",
year = "2011",
month = "12",
day = "1",
doi = "10.1016/j.contraception.2011.04.008",
language = "English",
volume = "84",
pages = "600--608",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "6",

}

A randomized study of the effect of mifepristone alone or in conjunction with ethinyl estradiol on ovarian function in women using the etonogestrel-releasing subdermal implant, Implanon®. / Weisberg, Edith; Croxatto, Horatio B.; Findlay, John K.; Burger, Henry G.; Fraser, Ian S.

En: Contraception, Vol. 84, N.º 6, 01.12.2011, p. 600-608.

Resultado de la investigación: Article

TY - JOUR

T1 - A randomized study of the effect of mifepristone alone or in conjunction with ethinyl estradiol on ovarian function in women using the etonogestrel-releasing subdermal implant, Implanon®

AU - Weisberg, Edith

AU - Croxatto, Horatio B.

AU - Findlay, John K.

AU - Burger, Henry G.

AU - Fraser, Ian S.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Background: Mifepristone alone or in combination with ethinyl estradiol (EE) can effectively stop an episode of uterine bleeding in women using the etonogestrel-releasing contraceptive implant, Implanon® but could impair contraceptive efficacy. Aim: To examine the effects of administration of mifepristone alone or with EE on ovarian function and cervical mucus consistency in women using Implanon. Study Design: Women using Implanon were randomized to mifepristone 25 mg twice daily on day 1 plus placebo 1 daily for 4 days or plus EE 20 mcg daily for days 2-5. Measurements of serum estradiol (E 2), progesterone (P 4), luteinizing hormone (LH), follicle-stimulating hormone (FSH), cervical mucus examination and maximal follicle size (by vaginal ultrasound) were carried out at various times. Results: Following mifepristone intake, there was a dramatic increase in E 2 levels ranging from 543 to 1183 pmol/L (p=.000), which was not correlated with maximal follicle size or preceded by LH or FSH increase. The increase in E 2 triggered an LH increase resulting in development of a luteinized follicle in four women with no evidence of ovulation. One of these women had estradiol and progesterone levels suggestive of ovulation, but no corpus luteum was seen. Almost all women had very low mucus scores, which did not correlate with E 2 levels. Discussion: Despite a transient increase in E 2 levels after mifepristone, there was no evidence of subsequent ovulation irrespective of whether they also received EE. The mechanism by which mifepristone in the presence of etonogestrel results in a rapid increase in E 2 levels remains unclear and could not be related to any significant changes in FSH, LH, ovarian follicle dynamics or subsequent possible ovulation. Conclusion: Pregnancy is very unlikely to occur if mifepristone and EE are given during use of Implanon to stop an episode of bleeding.

AB - Background: Mifepristone alone or in combination with ethinyl estradiol (EE) can effectively stop an episode of uterine bleeding in women using the etonogestrel-releasing contraceptive implant, Implanon® but could impair contraceptive efficacy. Aim: To examine the effects of administration of mifepristone alone or with EE on ovarian function and cervical mucus consistency in women using Implanon. Study Design: Women using Implanon were randomized to mifepristone 25 mg twice daily on day 1 plus placebo 1 daily for 4 days or plus EE 20 mcg daily for days 2-5. Measurements of serum estradiol (E 2), progesterone (P 4), luteinizing hormone (LH), follicle-stimulating hormone (FSH), cervical mucus examination and maximal follicle size (by vaginal ultrasound) were carried out at various times. Results: Following mifepristone intake, there was a dramatic increase in E 2 levels ranging from 543 to 1183 pmol/L (p=.000), which was not correlated with maximal follicle size or preceded by LH or FSH increase. The increase in E 2 triggered an LH increase resulting in development of a luteinized follicle in four women with no evidence of ovulation. One of these women had estradiol and progesterone levels suggestive of ovulation, but no corpus luteum was seen. Almost all women had very low mucus scores, which did not correlate with E 2 levels. Discussion: Despite a transient increase in E 2 levels after mifepristone, there was no evidence of subsequent ovulation irrespective of whether they also received EE. The mechanism by which mifepristone in the presence of etonogestrel results in a rapid increase in E 2 levels remains unclear and could not be related to any significant changes in FSH, LH, ovarian follicle dynamics or subsequent possible ovulation. Conclusion: Pregnancy is very unlikely to occur if mifepristone and EE are given during use of Implanon to stop an episode of bleeding.

KW - Ethinyl estradiol

KW - Etonogestrel

KW - Implanon®

KW - Mifepristone

KW - Subdermal implant

UR - http://www.scopus.com/inward/record.url?scp=81155134643&partnerID=8YFLogxK

U2 - 10.1016/j.contraception.2011.04.008

DO - 10.1016/j.contraception.2011.04.008

M3 - Article

C2 - 22078189

AN - SCOPUS:81155134643

VL - 84

SP - 600

EP - 608

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 6

ER -